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Background: NSCLC remains a challenging disease to treat, especially 
because the majority of patients present with advanced disease [1]. 
For many of these patients the standard first-line therapy is platinum-
based chemotherapy, which can prolong survival by 8–12 months in 
some patients and also improve disease-related symptoms [2]. The 
chemotherapy treatments are frequently poorly tolerated. Treat-
ment choices following chemotherapy are limited, approved options 
include docetaxel, pemetrexed and erlotinib. Recent developments 
with immunotherapies and approval of agents such as nivolumab and 
pembrolizumab [3, 4] are exciting. Other immunotherapy agents such 
as darvolumab, atezolizumab and avelumab are also investigated and 
show good results.
Materials and methods: Literature was reviewed about checkpoint 
inhibitors in metastatic NSCLC. Both the efficacy, patient reported 
outcomes and adverse events will be reported, with emphasis on the 
results from phase 3 trials.
Results: Checkpoint inhibitors in development are ipilimumab and 
tremelimumab, they block CTLA4. Nivolumab and pembrolizumab are 
blocking binding of PD1 to PDL1 and PDL2. Atezolizumab and dur-
valumab are blocking binding of PDL1 to PD1 and CD 80. Avelumab 
is in early stages of research. Nivolumab trials CheckMate 017 [5] and 
057 in second-line phase 3 trials and ChecMate 026 in 1st-line mono-
tharapy vs SOC phase 3 trial were reported. In second-line nivolumab 
showed superiority over docetaxel in progression free survival (PFS) 
3.5 vs 2.8 months, HR = 0.62, p- 0.004, mOS = 9.2 vs 6 months inde-
pendent to PDL1 expression in squamous histology. Adverse events 
were rare and manageable. Combination of nivolumab with chemo-
therapy and with erlotinib are being investigated. Pembrolizumab 
monotherapy showed responses which exceeded one year, median 
PFS = 6.3 months, especially high tumor proportion score (TPS) ≥50%, 
representing 23% of the screened NSCLC population. In pembroli-
zumab vs docetaxel, Keynote 010, median OS with pembrolizumab 
2  mg/kg and at least 50% PDL1 TPS was 14.9  months vs 8.2  months 
on docetaxel. Adverse events were less common on pembrolizumab. 
PDL1 expression ≥50% correlated with improved RR,PFS and OS 
regardless of histology. Smoking status was associated with increased 
RR. Keynote 024  =  pembrolizumab vs chemotherapy showed supe-
riority in phase 3, chemonaive patients of pembrolizumab in OS. 
(=Press release only) Atezolizumab vs docetaxel, phase 2 rand-
omized trial [6] POPLAR showed improvement in OS (HR 0.69 vs 0.73) 
in ITT population. Duration of response of 18.6  months compared 
to 7.2  months with docetaxel and well tolerated safety profile.OAK 
trial  =  phase 3 is ongoing. Durvalumab with trmelimumab phase 3 
trial results are pending.
Conclusion: The results of immunotherapy trials are encouraging, 
both from the point of improved efficacy and their tolerability. Com-
bination treatments with immunotherapy may further improve the 
efficacy and prolong the lives of the patients with metastatic NSCLC. 
These combination treatments will replace eventually the platinum 
doublets in first-line treatment of metastatic NSCLC
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Ovarian (OC) and Endometrial Cancer (EC) are still a challenge for 
gynecological oncologists because the treatment of the advanced 
disease remains an unmet need for patients. Some literature data 
confirmed the hypothesis of an immunogenic profile of both tumors. 
Some evidences showed an high mutational load and a unique 
mutational signature of BRCA1/2 mutated high grade serous ovarian 
cancers (HGSOCs) that probably harbor more tumor-specific neoan-
tigens and increased TILs and PD-1/PD-L1 expression [1]. The Cancer 
Genome Atlas Research Network (TCGA) recently provided a com-
prehensive genomic and transcriptomic analysis of OC and EC offer-
ing a new classification of those diseases, based on genetic features. 
Two analysis of gene profiling of high grade serous OC identified 
immunoreactive tumors (with a characteristic gene signature) that 
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subgroups [2, 3]. Other similar analysis on EC tumors, identified two 
among four subgroups (the polymerase epsilon [POLE]-ultramutated 
and the microsatellite instability [MSI]-hypermutated), that seem to 
present an enhanced immune microenvironment and a high muta-
tion burden [4, 5]. Immune checkpoint inhibitors (e.g., anti-PD-1 and 
anti-PD-L1 antibodies) have demonstrated remarkable efficacy against 
hypermutated cancers such as melanomas and lung carcinomas. One 
explanation for this effect is that hypermutated lesions harbor more 
tumor-specific neoantigens that stimulate recruitment of an increased 
number of tumor-infiltrating lymphocytes (TILs), which is counter-
balanced by overexpression of immune checkpoints such as PD-1 or 
PD-L1. Encouraging data support the relationship between the over-
expression of the PD-1/PD-L1 pathway in OCs and ECs with a higher 
genomic instability, and the activity of immunecheckpoint inhibitors 
[6, 7]. Those evidences suggest a rationale for testing the PD-1/PD-L1 
immunotherapy in these cancer subgroups.
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Background: Microsatellite instable (MSI) phenotype, as expression 
of mismatch-repair deficiency, characterizes tumors with high muta-
tional load and consequently increased production of immunogenic 
neoantigens [1]. These characteristics have been correlated with sus-
ceptibility to immune checkpoint inhibitors (CKI) [2]. Nevertheless, MSI 
is rare (34%) in renal cell carcinoma (RCC), although CKI are effective in 
a significant fraction of advanced tumors. We evaluated the hypoth-
esis that loss of heterozygosity (LOH) of relevant tumor suppressor 
genes (TSG) might provide a measure of tumor immunogenicity, con-
tributing as “the missing instability” to a high fractional allele loss (FAL) 
potentially underlying the rate of disease control obtained with CKI. 
We preliminary report the possible predictive value of LOH at different 
loci on 3p in patients with advanced RCC treated with the anti-PD-1 
Nivolumab.
Materials and methods: Only patients with assessable response 
according to the immune-related radiologic criteria were included. 
After DNA extraction from FFPE tissues of nephrectomy specimens, 
LOH study was performed by PCR for the microsatellite markers 
D3S1481 (3p14.2, FHIT gene) and D3S1478 (3p21.321.2). Non-inform-
ative (NI) cases due to homozygosity were subsequently tested for 
D3S1621 (3p21.2, LCTSGR1 gene). Non-informative cases for all loci 
were excluded. MSI was also assessed using two classical mononucleo-
tide markers, BAT-25 and BAT-26.
Results: Nine RCC cases evaluable for response were analyzed. All 
of them had microsatellite stable phenotype (MSS). Five cases (45%) 
presented LOH: three only at the FHIT locus (D3S1481), two at both 
3S1481 and D3S1478 loci. All these patients with LOH of at least one 
3p locus had good disease control and clinical benefit with Nivolumab: 
two had partial response and three had stable disease (SD). The 
remaining four cases were negative for LOH at the informative loci: 
three of them were clearly non-responsive to Nivolumab (confirmed 
progression disease) and one had SD.
Conclusion: These preliminary results suggest that LOH at 3p loci cor-
relates with good disease control with Nivolumab in advanced RCC 
patients. Our findings support the hypothesis that LOH at relevant 
genetic loci may provide a measure of mutational burden and of 
tumor immunogenicity and it could be used as predictive biomarker 
of response to CKI. Further analyses are planned with the aim to inves-
tigate other loci of key-TSG on 3p, 9p and 14p, evaluating the FAL 
index as potential more reliable predictive factor.
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Background: Localized radiation therapy (RT) can act as a powerful 
adjuvant to immunotherapeutic strategies by triggering de novo anti-
tumor immune responses to poorly immunogenic tumors. Radiation 
of tumor cells induces a dose-dependent release of ATP, a molecule 
that when released in the tumor microenvironment (TME) triggers 
recruitment and activation of dendritic cells (DCs), including CD103+ 
DCs recently identified as the key DC subset responsible for cross-
presentation of tumor-derived antigens to CD8+ T cells [1,2]. How-
ever, rapid hydrolysis of extracellular ATP by ecto-enzymes CD39 and 
CD73 results in a local accumulation of immunosuppressive adenosine 
(ADO) that inhibits DC activation and CD8+ T cell effector functions 
and enhances regulatory T cells (Tregs). By blocking CD73 in irradiated 
tumors, we tested the hypothesis that ADO generation limits the abil-
ity of RT to trigger anti-tumor immunity.
Materials and methods: Wild type (WT) or BATF3−/− mice (ablated 
development of CD8a+/CD103+ DCs) were inoculated s.c. with the 
poorly immunogenic breast cancer cell line TSA on day 0 and assigned 
to treatment with: (1) control Ab; (2) anti-CD73 (TY/23 Ab) (3) RT 
(20 Gy); (4) RT + TY/23. TY/23 (100 μg) was administered i.p. on day 11, 
14, 17 and 20. RT was given locally to the tumor as single 20 Gy dose 
on day 12. On day 18, some tumors were harvested for flow cytometry 
analysis of DCs and T cells. Mice were monitored for tumor progression 
by caliper measurements.
Results: In irradiated but not sham-treated mice, anti-CD73 Ab 
resulted in increased infiltration of CD103+DCs (8.9 ± 2.6% of DCs in 
RT +  anti-CD73 v. 3.5 ±  2.8% of DCs in RT, p  <  0.05) expressing ele-
vated levels of activation markers CD40 and CD86 compared to mice 
treated with RT alone. This change was associated with improved 
CD8+T cell/Treg ratio (5 ±  2.8 in RT +  anti-CD73 v. 0.8 ±  0.2 in RT). 
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Importantly, CD73 blockade had no effect by itself but improved sig-
nificantly radiation-induced tumor control (Tumor size at day 57 post 
inoculation: 385 ± 525 mm3 in RT + anti-CD73 v. 1036 ± 727 mm3 in 
RT). Consistent with the hypothesis that CD103+ DCs are essential for 
anti-tumor responses, the therapeutic effect of RT +  CD73 blockade 
was abrogated in BATF3−/− mice.
Conclusion: Our data indicate that ADO generated following RT plays 
a key role in hindering development of anti-tumor immune responses 
and identify, as a mechanism of this effect, an abrogated infiltration 
and activation of CD103+ DCs. Blockade of ADO generation by anti-
CD73 treatment constitutes a promising strategy to enhance radia-
tion-induced anti-tumor immunity.
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Elimination of virally-infected epithelial cells is mediated by CD8+ T cells 
and results in life-long protective immunity against reinfection. Simi-
larly, clinical data have shown that CD8+ T cells mediate the rejection of 
solid tumors and can confer long-term protection from disease recur-
rence when their activity is unleashed by immune checkpoint inhibi-
tors. Like viral proteins, mutated proteins expressed by an individual 
tumor are a source of powerful tumor-specific T cell epitopes. However, 
most of the cancer patients do not develop a sufficient number and 
repertoire of tumor-reactive T cells and are unresponsive to currently 
available immunotherapies. We have pioneered studies to explore the 
use of local tumor radiotherapy (RT) as a means to release tumor anti-
gens in an immunogenic context and induce anti-tumor CD8 T cells. 
We have demonstrated that RT in combination with anti-CTLA-4 elicits 
powerful and durable anti-tumor responses in pre-clinical models and 
in at least some patients (1, 2). Mechanistically, we have found that in 
tumors treated with RT + anti-CTLA-4 there is a marked increase in the 
CD8/CD4 ratio paralleled by an increase in clonality of the T cell recep-
tor (TCR) repertoire. Notably, unbiased clustering analysis of the TCR 
Vβ chain CDR3 sequences shows that there are unique clusters in each 
treatment group (RT alone, anti-CTLA-4 alone, RT +  anti-CTLA-4) that 
are not seen in untreated tumors. Importantly, most of the TCRs seen in 
the combination group do not overlap the TCR present in each mono-
therapy group, indicating that a unique TCR repertoire is generated by 
RT + anti-CTLA-4. Studies to optimize the vaccination effect of RT show 
that canonical pathways activated during viral infection are induced by 
hypofractionated (8GYX3) but not high single dose (20 or 30 Gy) RT and 
explain the differential ability of these RT regimens to synergize with 
anti-CTLA-4 in generating anti-tumor T cells and achieving abscopal 
responses. Overall, radiation-induced cancer cell-intrinsic activation of 
interferon type I pathway is absolutely required for the generation of 
systemically effective and lasting anti-tumor immunity against poorly 
immunogenic tumors.
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We have identified a cooperative interaction between local tumor 
RT (single fraction 12  Gy), intratumoral (IT) injection of IC hu14.18-
IL2 (anti-GD2 hu14.18 mAb linked to IL2), and checkpoint blockade 
with anti-CTLA4 mAb. C57Bl/6 mice were implanted with 2  ×  106 
B78 (GD2+) melanoma in one flank (1-tumor model). For mice bear-
ing a single 5 week (w) 200 mm3 tumor, RT + IT-IC results in complete 
response (CR) in 71% of mice and a tumor-specific memory T cell 
response. In the 2-tumor model, mice received 2 ×  106 B78 3  weeks 
(w) after the initial tumor implantation, in the opposite flank, and 
was ~50  mm3 at 5w, when RT begins. Surprisingly, RT +  IT-IC to the 
1st ~200 mm3 tumor, but not to the 2nd tumor, did not enhance 1st 
tumor shrinkage compared to RT alone and had no effect on the 2nd 
tumor. The 2nd tumor caused immune suppression, preventing RT and 
IT-IC from eliminating the 1st tumor. This was tumor-specific, as local 
RT + IT-IC to the 1st tumor was still effective if the 2nd was the unre-
lated Panc02 tumor. Delivering RT to both the 1st + 2nd B78 tumors 
eliminated the inhibitory effect of the 2nd tumor, enabling IT-IC to the 
1st tumor eradicated it in 64% of mice. Preliminary PCR and flow analy-
ses showed Tregs are better depleted by 1st tumor RT in mice with 1 
vs 2 tumors. In this 2 tumor model we combined RT + IT-IC of the 1st 
tumor with an IgG2a anti-CTLA-4 (that depletes Tregs); this rendered 
60% of mice disease-free (durable CR of both the treated 1st and the 
untreated 2nd tumors). Overall, local RT + IT-IC can result in long-term 
tumor eradication of large tumors via adaptive immunity to the “in situ 
vaccine”, provided that Treg-associated immune suppression from dis-
tant tumor is eliminated by RT or Treg-depletion.
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Anti-cancer vaccination is a promising approach to increase the effi-
cacy of checkpoint blockade therapies. There exists a broad range 
of vaccine formulations, each with their unique benefits and limita-
tions. Clinically, the vaccine most commonly used in combination 
with checkpoint blockade is based on peptide antigen formulated in 
mineral oil, also known as incomplete Freund’s Adjuvant (IFA). How-
ever, the landmark FDA registration trial for anti-CTLA-4 therapy (Ipili-
mumab) revealed a complete lack of benefit of adding vaccination 
with gp100 peptide formulated in IFA, and in fact demonstrated a sig-
nificant reduction in initial disease control. Upon modeling this com-
bination therapy in mice, we found that gp100 peptide in IFA induces 
gp100-specific Teff which become sequestered at the vaccination site 
and cause local inflammation. The inflamed vaccination site subse-
quently also sequesters and destroys the systemic pool of anti-CTLA-4 
induced Teff with specificities for tumor antigens other than gp100, 
reducing the anti-tumor efficacy of anti-CTLA-4 therapy. We identify 
key mechanistic mediators of T cell sequestration, as well as alternative 
vaccine approaches that do not induce these undesirable effects and 
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instead potently synergize with anti-CTLA-4 and anti-PD-1 checkpoint 
blockade, causing markedly increased anti-tumor activity. These find-
ings point the way to rational design and selection of cancer vaccine 
formulations that synergize with checkpoint blockade therapy.
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Cells of the immune system, e.g., CD8 T cells and Natural killer (NK) 
cells are capable of recognizing and killing cancer cells. Moreover, sev-
eral lines of evidence suggest that the naturally elicited anti-cancer 
immune responses lead to infiltration of immune cells into tumors 
and the presence of these cells have an impact on disease progression, 
i.e., overall survival of the patient. Harnessing of the immune system 
to combat cancer i.e., cancer immunotherapy, is revolutionizing treat-
ment of patients today. To this end, administration of immune check 
inhibitory monoclonal antibodies is approved for the treatment of 
several solid cancer indications, and although predictive markers are 
still missing, patients with a brisk tumor infiltration of immune cells 
are more prone to respond to treatment. Moreover, immune cells infil-
trating into the tumor can be directly utilized in therapy by adminis-
tration of in  vitro expanded tumor infiltrating lymphocytes (TIL). In 
our clinical trials based on TIL therapy we have experienced massive 
tumor regressions in melanoma patients, some of which experience 
potentially curative complete responses. The success of TIL therapy 
in melanoma, clearly builds on the presence of tumor specific T cells 
at the tumor site, and underscores the need to define ways as how to 
increase immune cell infiltration to the tumor site. Regular exercise 
reduces the risk of cancer and disease recurrence, by largely unknown 
mechanisms. We recently demonstrated that voluntary wheel running 
showed over 60% reduction in tumor incidence and growth across 
several murine tumor models. Microarray analysis revealed exercise-
induced up-regulation of pathways associated with immune func-
tion, prompting further investigations. Immune cell infiltration was 
significantly increased in tumors from exercising mice, and depletion 
of NK cells enhanced tumor growth and blunted the exercise-depend-
ent suppression. Moreover, NK cells were engaged through an epi-
nephrine-dependent mobilization, and blockade of this pathway by 
β-adrenergic blockade blunted the exercise-dependent tumor inhibi-
tion. Together these results link exercise with improved immunologi-
cal control of tumor progression, suggesting that exercise could be a 
beneficial partner for immunotherapy.
World‑wide immunoscore task force
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Background: A main goal of a modern Clinical Pathology Division is 
to provide clinicians involved in the treatment of tumor patients with 
fast and precise histopathology reports that include information on the 
TNM stage and potential prognostic and predictive biomarkers. In colo-
rectal cancer, the immunoscore based on immune markers CD3 and 
CD8 is a promising prognostic approach using immunohistochemistry 
and a digital scoring system. Nevertheless, there is still the challenge of 
implementing the immunoscore in daily diagnostic practice in surgical 
pathology. The aim of the study is to present one of the first histopa-
thology labs designed upon the LEAN management system which will 
allow a pragmatic and solid implementation of the immunoscore.
Materials and methods: Our Clinical Pathology Division was organ-
ized into three subunits (MDs, technicians and secretaries) and coor-
dinated strategically and operatively by a staff supported by a LEAN 
Officer. The following measurements were introduced: reconstruction 
of the histopathology lab based on the LEAN principles such as stand-
ardized working places and continuous workflow, introduction of a 
diagnostic wing including six sign-out rooms for the MDs and moni-
toring of the diagnostic process by key performance indicators such as 
turn-around-times (TAT).
Results: The distance travelled by a resection specimen was shortened 
from 561 to 56  m, batch processing dramatically reduced specimen 
waiting times and the TAT were reduced from 90 h to an average of 48 
for resection specimens and from 55 to 32 h for biopsies, respectively. 
A LEAN histopathology lab allows a proposal for an Immunoscore 
Workflow definition: (1) selection of the tumor block by a pathologist; 
(2) staining by the immunohistochemistry lab; (3) scanning and prepa-
ration of the stained slides by technicians; (4) control and reporting by 
a pathologist.
Conclusions: The implementation of the immunoscore into surgical 
pathology on the operative level needs a well-defined strategy which 
is simple, applicable and user-friendly. Therefore, it is mandatory that 
surgical pathology divisions and digital pathology development units 
test novel and promising digital scoring systems before the implemen-
tation in the daily diagnostic practice based on working processes 
using SOPs and TATs.
System biology session: Molecular
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Although melanoma patients with BRAF mutations benefit from the 
therapy with BRAF/MEK inhibitors, they invariably develop resistance. 
Our laboratory is interested in the study of the mechanisms responsible 
for the establishment of drug resistance, and in particular in non-muta-
tional adaptive changes. Since miRNAs are powerful post-transcriptional 
regulators of gene expression and play a key role in cancer we decided 
to assess their possible involvement. Using a bioinformatic approach 
we recently identified miR-579-3p, as a potential regulator of mela-
noma progression. Low miR-579-3p expression correlates with disease 
progression and expression is further decreased in BRAFi/MEKi resist-
ant melanoma cells. miR-579-3p suppresses melanoma cell growth 
and migration while enhancing apoptosis alone or in combination with 
BRAF and/or MEKi. Moreover, miR-579-3p forced expression impairs the 
establishment of resistance to BRAFi. Mechanistically miR-579-3p acts by 
targeting both BRAF, and MDM2 oncogenes. In matched tumor samples 
from melanoma patients before and after development of resistance, 
we observed a reciprocal regulation of the expression of miR-579-3p 
and of BRAF and MDM-2. More recently using the Nanostring™ platform 
we started to assess changes in the whole miRNome profile during the 
development of drug resistance in vitro in two different BRAF-mutated 
melanoma cell lines. Bioinformatic analysis of Nanostring™ data 
revealed a stepwise deregulation of a growing number of miRNAs. Path-
way analysis uncovered rewiring of a complex network of intracellular 
pathways capable to affect the expression of secreted pro-inflamma-
tory and pro-angiogenic cytokines, which was confirmed empirically. 
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In summary our findings identify a network of deregulated miRNAs as 
major players in the establishment of drug resistance in melanoma.
Combination strategy session
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Where are we really with clinical trials of combination 
immunotherapy?
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An incredible number of clinical trials are testing various immuno-
therapy agents in combination strategies. This talk will summarize 
where we stand with various immunotherapy combinations and stress 
general principles to consider in ongoing and future combination 
immunotherapy studies. Although this talk will include data for the 
ipilimumab and nivolumab combination, many other combination 
immunotherapy regimens will be discussed.
System biology session: Immunology
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A subset of patients with cancer have evidence of a spontaneous 
anti-tumor immune response and T cell infiltration into tumor sites. 
This can be quantified most robustly via gene expression profiling 
and has been described as the “T cell-inflamed tumor microenviron-
ment”. This phenotype has prognostic significance and is associated 
with the presence of microenvironmental factors such as PD-L1, 
IDO and T regulatory cells. Clinical response to immunotherapeu-
tics such as anti-CTLA4 and anti-PD1 antibodies in multiple cancers 
is highly associated with the T cell-inflamed tumor microenviron-
ment. Alternatively, the non-T cell-inflamed microenvironment is 
unresponsive to current immunotherapy approaches. With the 
development of multi-dimensional genomic databases such as The 
Cancer Genome Atlas, the potential has arisen to use large scale bio-
informatic approaches to investigate differences between tumors on 
a molecular level. Using a 160 gene T cell based RNA signature as a 
phenotype, strong associations between tumor-intrinsic signaling 
pathways, germline single-nucleotide polymorphisms and commen-
sal microbiome have been identified with the presence or absence 
of the T cell-inflamed tumor microenvironment. These findings are 
being validated in vivo. Through this frame work rationale combina-
tion immunotherapy drug development directed toward either the 
T cell-inflamed or non-T cell-inflamed tumor microenvironment is 
being advanced in clinical trials. Specific focus is given to the next 
major hurdle in cancer immunotherapy: overcoming the non-T cell-
inflamed tumor microenvironment.
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Advances in dendritic cell cancer immunotherapy
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Background: Dendritic cell (DC) vaccines are in clinical trials for sev-
eral types of cancer. Our laboratory has been working to improve 
DC vaccine therapy through the discovery of potency markers and 
improving vaccine production methods.
Materials and methods: We have been treating patients with prostate 
cancer using DCs pulsed with T cell receptor γ alternate reading frame 
protein (TARP) peptides and patients with breast and other human 
epidermal growth factor receptor 2 (HER2/neu) expressing cancers 
with DCs transduced with an adenoviral vector expressing HER2/neu 
(adHER2/neu). For both clinical trials DCs are being manufactured 
using peripheral blood mononuclear cell (PBMC) concentrates that 
have been enriched for monocytes using counter-flow elutriation. The 
monocytes are cultured with IL-4 and GM-CSF to produce immature 
DCs and then with lipopolysaccharide (LPS) and interferon gamma to 
produce mature DCs. During the 4 days required to manufacture the 
DCs the cells are cultured in RPMI-1640 media supplemented with 
10% autologous plasma. We evaluated the transcriptome, secretome 
and phenotype of TARP DCs and investigated DC characteristics 
associated with clinical and immunological responses. DC showing 
a lower expression of a tolerogenic gene signature induced a strong 
antigen-specific immune response as well as slowing in PSA velocity, 
a surrogate for clinical response. DCs from patients with clinical and 
immunological responses were also characterized by lower surface 
expression of CD14, lower secretion of IL-10 and MCP-1 (CCL2) and a 
greater secretion of MDC (CCL22).
Results: During the manufacture of adHER2/neu DCs we found for 
some patients that the use of autologous plasma as a culture media 
protein supplement was associated with poor levels of HER2/neu 
expression. The production of DCs with monocytes from these same 
patients using plasma from healthy subjects yielded high levels of 
gene expression. A mixture of healthy donor and patient plasma 
resulted in low transduction levels indicating a factor in patient 
plasma inhibited gene transfer. Inhibitory factors were found in the 
plasma of 8 of 21 patients treated. A comparison of adHER2/neu DCs 
manufactured with inhibitory patient and healthy donor plasma found 
that DCs manufactured with inhibitory plasma had greater expression 
of CCR7 (CD197) and CD14 and were enriched in IL-10 and IL-6 path-
ways genes. These results suggest that cytokines in the serum of can-
cer patients effects that production of DC vaccines and these factors 
may contribute to systemic immune suppression.
Conclusion: In conclusion, the expression CD14 and the secretion of 
IL-10, CCL2 and CCL22 may be useful DC vaccine potency markers. 
While the use of autologous plasma for DC manufacturing prevents 
the exposure of the vaccine recipient to transfusion transmitted dis-
eases, autologous plasma from some patients contains factors that 
affect adenoviral vector gene transfer and possibly the function of 
DCs. Further study of these inhibitor factors is warranted to deter-
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It has been known for some time that malignant transformation of 
cells may be associated with defects in the expression and/or func-
tion of HLA class I antigen processing machinery (APM). This machin-
ery plays a crucial role in the synthesis and expression of HLA class I 
antigen-tumor antigen (TA) derived peptide complexes. These com-
plexes mediate the recognition of tumor cells by cognate T cells. Mul-
tiple molecular mechanisms have been shown to underlie defects in 
the expression and/or function of HLA class I APM. These defects may 
cause abnormalities in the synthesis and/or expression of HLA class I 
antigen-TA derived peptide complexes. These abnormalities may lead 
to a defective or lack of recognition of tumor cells by cognate T cells, 
thus providing tumor cells with an escape mechanism from host’s 
immune system. These functional abnormalities have been suggested 
to represent a mechanism underlying the association found in many 
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types of malignancies between down regulation or lack of HLA class 
I APM component(s) in tumor cells and poor clinical course of the 
disease.
This presentation will discuss (1) the steps which may lead to the gen-
eration of tumors with defects in HLA class I APM component expres-
sion and/or function with special emphasis on the role of selective 
pressure in the generation of tumors with this phenotype and (2) the 
potential role of HLA class I APM defects in the innate and acquired 
resistance to immunotherapy with checkpoint inhibitor-specific mon-
oclonal antibodies. In addition strategies to overcome this resistance 
will be described.
Melanoma Bridge 2016: oral presentations
Evolving topics in cancer immunotherapy
O3 
Altering the gut microbiota to improve responses to immune 
checkpoint blockade
Connie P. M. Duong1,2, Marie Vetizou1,2, Laurence Zitvogel1,2,3,4 
1Gustave Roussy Cancer Campus, Villejuif, France, 2INSERM Unit U1015, 
Villejuif, France, 3Université Paris Sud, Université Paris‑Saclay, Faculté de 
Médecine, Le Kremlin Bicêtre, France, 4Center of Clinical Investigations in 
Biotherapies of Cancer 507, Villejuif, France
Correspondence: Connie P. M. Duong ‑ CONNIE.DUONG@gustaver‑
oussy.fr
Journal of Translational Medicine 2016, 15(Suppl 1):O3
Background: The targeting of the immune checkpoint CTLA4 in 
melanoma patients has led to increased objective response rates and 
subsequent approval by the EMA and FDA. However, studies have 
also reported that some patients have experienced immune-related 
adverse events, often occurring at sites exposed to commensal micro-
biota, leading to cessation of treatment. Our lab and others have dem-
onstrated that the gut microbiota impacts the efficacy of checkpoint 
blockade therapy [1, 2]. We have shown that Bacteroides species play 
an important role on the efficacy of CTLA4 blockade in the treatment 
of melanoma. Analysis of feces from metastatic melanoma patients 
led to the identification of three clusters (A, B and C) based on genus 
composition. Here we present a follow up study, where we hypothe-
sise that compensating Cluster B patient transplanted mice with live 
or immunogenic bacteria, termed oncomicrobiotics, can increase the 
efficacy of anti-CTLA4 treatment. Given recent data showing that the 
co-blockade of CTLA4 and PD1 has a significantly greater response 
rate compared to targeting CTLA4 alone [3], we also wanted to investi-
gate the impact of microbiota on this combination.
Materials and methods: To test this, SPF mice were treated with or 
without a cocktail of antibiotics (ATBx) composed of ampicillin, strep-
tomycin and colistin. Mice were subsequently gavaged with patient 
feces from different clusters and inoculated with the sarcoma cell line, 
MCA205. Mice were then treated with five doses of anti-CTLA4 Ab, 
gavaged with defined species of oncomicrobiotics and monitored for 
tumor growth and survival. In order to evaluate the effect of the gut 
microbiota on the combination, mice were treated with or without 
ATBx, inoculated with either MCA205 or the melanoma cell line RET, 
and treated with anti-CTLA4, anti-PD1, or a combination of both Abs.
Results: Consistent with our previous data, mice which received feces 
from Cluster C patients had a significantly greater response to CTLA4 
blockade compared to mice which received Cluster B feces. Mice that 
has been colonised with Cluster B feces had a significantly greater 
response to anti CTLA4 therapy when compensated with oncomicro-
biotics. We also found that the efficacy of anti CTLA4 and anti PD1 
blockade is partially dependent on an intact microbiome, as dysbi-
otic mice had a significantly reduced response to the combination 
treatment.
Conclusions: It is anticipated that this work will increase the thera-
peutic coverage of immune checkpoint blockade treatment when 
appropriate oncomicrobiotics are co-administered, resulting in 
increased durable responses in patients with metastatic melanoma.
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Background: Therapy of melanoma has been improved by the advent 
of immunological checkpoint inhibitors and by targeted therapies 
with kinase inhibitors [1]. However, the efficacy of targeted thera-
pies against BRAFV600 mutations is hampered by the development of 
acquired resistance [2–3]. Treatment failures in melanoma patients 
have been attributed in part to the presence of cancer stem cells 
(CSCs). Observations that CSC have a distinct biology when compared 
to that of the bulk tumor cells and, more importantly, are resistant 
to chemotherapies, suggest their involvement in invasion, metasta-
sis and relapse [4]. We previously demonstrated that lung CSCs are 
enriched for the expression of SCD1, a key enzyme of lipid metabolism 
involved in the conversion of saturated into mono-unsaturated fatty 
acids, and that its inhibition suppresses the ability to form spheroids 
and selectively kills CSCs[5]. In this study we investigated the involve-
ment of SCD1 in melanoma stem cells survival and the interplay 
between BRAF/ERK inhibitors (BRAF/MEKi) and lipid metabolism.
Materials and methods: Bioinformatics analysis of published melanoma 
datasets was performed using online tool (http://www.cbioportal.org/). 
SCD1 gene expression data of 479 patients were downloaded from TCGA 
and correlated with survival. Combination of BRAF/MEKi and the SCD1 
inhibitor MF438 were tested by spheroid forming assays on two BRAF-
mutated melanoma cell lines (M14 and WM115) grown in selective 3D 
medium. SCD1, Nanog, Oct4 expression was studied by WB and RT-PCR.
Results: Bioinformatics analysis of public datasets was carried out 
to assess if SCD1 can act as prognostic factor in melanoma. By using 
online tool we found that overall survival of patients affected by 
melanoma was inversely correlated to SCD1 expression. This finding 
led us to measure SCD1 expression in CSCs obtained from WM115 
and M14 cell lines. Preliminary results showed that SCD1 expression 
is upregulated in spheroids derived from both lines. Moreover SCD1 
overexpression was associated with enrichment of stemness markers. 
Exposure to high doses 10–20 μM of Vemurafenib or MEK162 induced 
increased spheroid formation. Based on these evidences we analyzed 
the functional role of SCD1 by inhibiting its activity using MF438. We 
found that spheroids were resistant to BRAF/MEKi and expressed high 
levels of Oct4 and Nanog. Furthermore we observed that combining 
BRAF/MEKi with MF438 inhibited synergistically spheroid growth.
Conclusions: Our results suggest that treatment of BRAF-mutated 
melanoma cells with BRAF/MEKi selects for cells with stem cell features 
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and that this phenomenon is counteracted by SCD1 inhibitors. These 
findings have potential implication of the development of new com-
bination therapies.
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Background: The incidence of MM progressively increases and today 
16 cases/100,000 cases per year are expected in Italy. However, there 
are major differences between geographical areas. In northern Italy 
the risk is double of that in the southern regions. The screening cam-
paigns led to the identification of many early forms of MM, resulting 
in increased incidence of the disease, but have not changed mortality. 
This is possibly related to the identification of melanomas that would 
have remained silent. It should be remembered that the visit and 
the dermoscopy are operator-dependent methods and that requires 
long experience for their optimal use. Even in the most experienced 
hands, the sensitivity of these methods does not exceed 85% and 90%, 
respectively. The identification of new effective screening methods, 
able to eliminate the existing limits, is needed. MM is the skin cancer 
with the worst prognosis, especially when discovered at advanced 
stages. Moreover, it would be clinically relevant to identify in advance 
the melanoma lesions at risk of recurrence.
Materials and methods: In 2014 we have activated an ongoing 
experimental study to investigate the possible role of miRNA in MM 
screening tool. All the subjects clinically screened (including derma-
toscopy) by the “Lega Italiana per la Lotta contro i Tumori” (LILT) are 
invited to join the study. They undergo a blood sample collection and 
a panel of 15 miRNAs is analyzed. The primary objective is to compare 
the level of miRNAs in patients with MM and non-neoplastic skin pig-
mented lesions, to evaluate their diagnostic value. The study foresees 
to enroll 700 subjects, to find at least 100 MM.
Results: From September 2014 to April 15, 2016, we accrued 546 sub-
jects, who had a suspicious skin lesion. 5 people have not performed 
excision (patient’s refusal or dermatological second opinion); 87 (16%) 
had a histological diagnosis of MM. Specifically we found 37 in  situ 
MM, 50 infiltrating, including 15 pT1a, 19 pT1b, 4 pT2a, 2 pT2b, 1 pT3a, 
4 pT3b, 2 pT4b. One patient was diagnosed with multifocal mucosal 
melanoma; in 2 MM patients pathological staging is under progress.
Conclusions: The study is ongoing and biomolecular data are not 
yet available. However, it gives in a prospectic way, preliminary 
information about the incidence of MM in a population clinically 
screened and carrying suspected skin lesions.
Acknowledgements: This project is supported by CRC Foundation 
and LILT.
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Background: Immunotherapies for cancers, including melanoma, 
have made great strides in recent years, yet new and improved 
approaches are required to achieve more durable responses in a 
greater number of patients. The in  vitro expansion phase of adop-
tive T cell therapy prior to reinfusion into the patient provides the 
opportunity to genetically enhance T cell subsets to improve in  vivo 
performance. While the most common genetic modification is the 
incorporation of engineered antigen-specific TCRs or chimeric antigen 
receptors [1, 2], modification to signaling pathways in T-cell memory 
subsets in order to enhance T cell sensitivity is an underexplored strat-
egy. This is mainly because contributions of TCR signaling components 
that confer differences in activation sensitivity and functional out-
comes between CD8+ Tcm and Tem are unclear.
Materials and methods: To understand how TCR-proximal signaling 
differs significantly between T-cell memory subsets, we derived TCM 
and TEM [3] from the humanized TCR-transgenic melanoma mouse 
model (JR209) [4]. We quantified differences in TCR activation and 
feedback regulation by novel live-cell imaging technologies, phospho-
specific protein assays and used modeling of early TCR signaling to 
reveal the physiological significance of these differences [5].
Results: One of the critical steps of T cell triggering is the coordinated 
phosphorylation and binding of CD3 and Zap-70 by Lck following 
TCR ligation by Pmhc [6, 7]. Here, we show that Tcm and Tem possess dif-
ferential constitutive Lck activities [8]. Immediately proximal to Lck 
signaling, we observed enhanced Zap-70 phosphorylation in TEM 
following TCR ligation compared with TCM. Further, we observed 
increased intracellular calcium influx and cytotoxic effector function in 
TEM compared with TCM, and provide evidence that this results from 
a lower probability of TCM reaching threshold activation signaling due 
to the decreased magnitude of TCR-proximal signaling. We show that 
the differences in Lck constitutive activity between CD8+ Tcm and Tem 
are driven in part by differential regulation by SH2 domain-containing 
phosphatase-1 (Shp-1) and C-terminal Src kinase (Csk). We demon-
strate that inhibition of Shp-1 results in increased constitutive Lck and 
cytotoxic activity in TCM to levels similar to that of TEM.
Conclusions: Together, this work demonstrates that differential activi-
ties of TCR-proximal signaling components may contribute to estab-
lishing the divergent effector properties of TCM and TEM. Inhibition of 
negative regulatory molecules, for example Shp-1 or Csk, or gener-
alized augmentation of T cell sensitivity with miRNA offer potential 
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therapeutic approaches in T cell immunotherapy but must be consid-
ered in the context of specificity and optimal targeting.
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Background: Immunotherapeutic modalities of cancer treatment 
have been increasingly gaining ground in the past few years. Antibod-
ies targeting immune regulatory pathways showed unprecedented 
clinical efficacy in patients with advanced cancers. Nevertheless, 
generally only a smaller proportion of patients benefit from these 
therapies, prompting a search for biomarkers that could help identify 
patients likely to benefit from the treatment. Although several candi-
dates have been suggested, no validated predictive biomarkers are 
available yet.
Materials and methods: Our study was performed on archived par-
affin blocks of surgical samples excised within one year before ipili-
mumab therapy from patients with metastatic melanoma (30 patients, 
1–25 lesions per patient). Eighty-six samples were analyzed, 52 nodal 
and 34 subcutaneous/cutaneous metastases. Immunohistochemi-
cal analysis was performed for detection of 10 immune cell markers 
(CD8, CD45RO, CD20, CD134, CD137, FOXP3, PD-1, CD16, CD68 and 
NKp46). Intratumoral density of the labeled cells was determined and 
evaluated in relation to response to ipilimumab treatment and disease 
outcome.
Results: For most of the markers studied, median immune cell den-
sities were at least 2 times higher in lymph node metastases com-
pared to subcutaneous/cutaneous ones, therefore, the prognostic 
and predictive associations of immune cell infiltration were evaluated 
separately in the two groups of metastases as well as in all samples 
together. Thirteen patients were considered responders showing com-
plete or partial response, or stable disease for at least 6 months. Higher 
prevalence of immune cells expressing the FOXP3, CD8, CD20, NKp46, 
or CD134 marker was seen in lymph node metastases of the respond-
ers compared to non-responders. Kaplan–Meier analysis of survival 
revealed that high mean density of immune cells in nodal metastases 
was associated with significantly longer progression-free and overall 
survival in the case of the majority of cell types studied. In subcutane-
ous/cutaneous metastases, on the other hand, correlation with treat-
ment response or with survival was limited to the CD16, CD68 and 
NKp46 markers.
Conclusions: Our findings corroborate previous results indicating 
stronger response to ipilimumab treatment in cases of an immuno-
logically active tumor microenvironment. Studies on larger patient 
cohorts are required to prospectively validate infiltrating immune cell 
densities as biomarkers of ipilimumab efficacy and, possibly, to inves-
tigate their predictive value in the case of anti-PD-1/PD-L1 agents as 
well as of other immunotherapy approaches.
The work was supported by the National Research, Development and 
Innovation Office NKFI Grant 105132.
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Background: Melanoma is the fourth and sixth most common malig-
nancy in men and women, respectively, and the 5-year survival rate 
critically depends on disease stage (American Cancer Society, 2016). 
MicroRNAs (miRNAs) are small, non-coding, single-stranded RNAs 
endogenously produced by the cells, which regulate the expression of 
hundreds of target genes. Circulating miRNAs actively secreted by tumor 
cells or released as the consequence of tumor cell death, have been 
proposed as potential biomarkers in cancer patients because of their 
stability in body fluids, resistance to endogenous RNase and constant 
expression in healthy individuals (Mitchell et al. 2008; Chen et al. 2008).
Materials and methods: In the current study, the expression profiles 
of a selected panel of circulating miRNAs were analysed in plasma 
samples derived from patients and healthy donors to identify possible 
candidate biomarkers for diagnosis, prognosis and/or surveillance of 
human cutaneous melanoma. The study protocol was approved by 
local Ethics Committee and conducted in accordance to the principles 
of the Declaration of Helsinki. Blood samples were collected from mel-
anoma patients (n = 30) at different disease stages, and from healthy 
age- and sex-matched volunteers (n = 32). Plasma miRNAs were iso-
lated by miRNeasy Serum/Plasma Kit (Qiagen) and real-time PCR were 
carried out using miRCURY LNATM Universal RT microRNA PCR system 
(Exiqon, Denmark). Data analysis was carried out using two different 
strategies for normalization: Global Mean Normalization (GMN) and 
NormFinder model.
Results: The GMN approach and NormFinder algorithm provided 
13 and 7 significantly dysregulated miRNAs (p  <  0.05), respectively, 
and those that resulted significantly dysregulated after normali-
zations and the Bonferroni correction were selected. Circulating 
miR-15b-5p (p  =  1.34e−05), miR-149-3p (p  =  3.40e−12), and miR-
150-5p (p  =  2.85e−12) were up-regulated, while miR-193a-3p 
(p  =  1.30e−06) and miR-524-5p (p  =  2.41e−05) were down-regu-
lated in patients (regardless of disease stage) compared to healthy 
controls. Linear regression and following receiving operator curves 
(ROC) analyses were performed to evaluate the diagnostic value of 
these five selected miRNAs (i.e., the ability to discriminate between 
cases and controls). The area under ROC curve (AUCs) for individual 
miRNAs ranged from 0.801 to 0.951. Although the predictive power 
of all selected miRNAs was clearly demonstrated, miR-150-5p and 
miR-149-3p gave the best performance (AUCs of 0.9489, 95% CI from 
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0.8852 to 1.017 and 0.9510, 95% CI from 0.8852 to 1.017, respectively). 
Noteworthy, predictive performance was further improved when con-
sidering the double combination of miR-150-5p and miR-149-3p. The 
double classifier has indeed an increased area under ROC curve (AUC) 
of 0.966 (95% CI 0.938–0.994) with 90% sensitivity, 68% specificity.
Conclusions: In conclusion, findings of the current pilot study iden-
tified five circulating miRNAs in melanoma patients, of which three 
detected for the first time as circulating in this type of cancer, as 
potential diagnostic biomarkers with high sensitivity and specificity. 
In particular, the combined miR-149-3p, miR-150-3p and miR-193a-3p 
signature showed a high capacity to discriminate between healthy 
subjects and affected individuals. This feature make the signature 
suitable to be used in controversial melanoma diagnosis. Indeed, 
these preliminary data that identify a new panel of three miRNAs, 
including two identified for the first time as circulating in melanoma, 
deserve to be validated in a larger number of patients, in order to 
confirm their diagnostic power not only as a possible support to con-
troversial pathology reports histological results but also in early diag-
nosis of melanoma.
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Background: Nowadays, the biomolecular mechanisms at the basis 
of malignant melanoma development and progression are still poorly 
understood. Although several studies were conducted in order to 
associate single nucleotide polymorphisms (SNPs) frequencies with 
the carcinogenesis and tumors outcome, malignant melanoma litera-
ture data are inconclusive [1-14].
In our study we evaluate the impact of different genotypes for phos-
phoinositide 3 kinase (PI3K) and vitamin D3 nuclear receptor (VDR) 
SNPs on melanoma patients’ outcome.
Materials and methods: Genomic DNA of 88 patients was extracted 
from blood and Formaldehyde Fixed-Paraffin Embedded samples. 
Gene polymorphisms were determined by Real-Time Polymerase 
chain reaction (PCR) using TaqMan assays [15]. We selected polymor-
phisms of the regulatory and catalytic subunit of PI3K encoded by 
PIK3CA [16] and PIK3R1 [17] genes, respectively. In particular, we ana-
lyzed rs2699887C > T of PIK3CA and rs3730089G > A of PIK3R1 SNPs. 
Furthermore we considered the following VDR SNPs: rs2228570A > G 
(Fok1), rs731236A > G (Taq1) and rs1544410C > T (Bsm1).
Progression free survival (PFS) and overall survival (OS) were estimated 
with the Kaplan–Meier method and with Mantel–Haenszel log-rank 
test [18].
Results: The statistical analysis for rs2699887C  >  T of PIK3CA, 
rs3730089G > A of PIK3R1, Taq1 and Bsm1 of VDR didn’t result in statis-
tical significant differences in PFS and OS.
On the contrary, Fok1 of VDR showed a significant difference 
in PFS after the first line therapy in the analyzed population 
(median PFS  =  21.2  months of homozygous recessive genotype 
vs. 3.3  months of homozygous dominant and heterozygous ones, 
p  =  0.03). In particular, in homozygous recessive patients for Fok1 
SNPs of VDR a high rate of histological regression and BRAF mutation 
were observed. Furthermore, more efficacy of BRAF +/- MEK inhibi-
tors therapies vs. homozygous dominant and heterozygous ones 
was shown.
Conclusions: Few studies, from the published literature, associate 
malignant melanoma patients’ outcome with VDR SNPs [7, 19, 20]. Our 
study demonstrated a significant correlation between homozygous 
recessive genotype of Fok1 SNPs of VDR gene and an increased PFS in 
patients who underwent a first line therapy with BRAF inhibitors.
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Background: Patients with Down syndrome are at low risk for develop-
ing solid tumors—such as carcinoma of the lung, breast and cervix. Tes-
ticular cancer would be the only one with a higher risk than the healthy 
population [1]. We present the case of a patient with Down syndrome 
with a history of seminoma of the testis, and melanoma of the back.
Materials and methods: A male patient, aged 31, suffers from Down’s 
disease (Trisomy 21 free) with autism, lactose intolerance and with a 
history of right testicular seminoma (pT2N0) to age of 27 years. Having 
find this, inguinal orchiectomy was performed followed by an admin-
istration of carboplatin with disease control. Four years later he came 
for one of the follow-up feedback oncological check planned for semi-
noma, presenting an atypical pigmented lesion of the back during. 
The nodule had the following dermoscopic features: nodular lesion 
of hypopigmented area with gray-blue veil, atypical pattern, irregular 
peripheral blood cells. The patient was subjected to intervention by 
surgical excision under general anesthesia for suspected melanoma 
which was followed surgical radicalization and research limphonode 
sentinel (1.42 mm Breslow, mitotic rate 6 mm2).
Results: The LNS was negative immunohistochemical investigation 
and there were no surgical complications (wound dehiscence, sovrin-
fezione, seroma etc.)
Conclusion: Down’s syndrome has an increased risk of onset of solid 
tumors only in case of seminoma; trisomy 21 would be protective 
against some solid tumors, such as lung cancer, breast, cervix and mel-
anoma [2]. We report a case of a patient with Down syndrome with a 
history of testicular seminoma and metachronous occurrence of mela-
noma on the back.
Consent to publish: Authors have written informed consent from the 
patient to publish.
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Background: Melanoma is a highly aggressive form of skin cancer that 
originates from malignant transformation of melanocytes or from their 
neural crest-derived multipotent precursors. The aggressive behav-
ior of melanoma is correlated with its histological features, such as the 
thickness of the primary tumor and the mitotic index. Identification of 
predisposing genes implicated in melanoma progression is crucial to 
better understand this disease and improve its treatment. In recent years, 
genomic sequencing studies have uncovered mutations in multiple 
genes in melanoma [1-3]. However, the majority of these studies have 
investigated metastatic or advanced primary melanomas, but data on 
early stages are very limited. Here we performed a comparative analysis 
of thin (<1 mm) and thick (>4 mm) melanomas using exome sequencing.
Materials and methods: 5 thin (<1 mm) and 5 thick (>4 mm) untreated 
fresh-frozen primary cutaneous melanomas and their matched periph-
eral blood were collected and processed for DNA isolation. Exome 
sequencing was performed using Illumina. Somatic Single Nucleotide 
Variants (SNVs) and small Insertion/Deletions were analyzed by MuTect, 
and Somatic Copy Number Alterations (SCNAs) were detected with 
EXCAVATOR. Two public available microarray data sets (GEO-46517 and 
GDS3966) were used to assess expression of genes involved in regions 
of copy loss and gain. The effect of specific mutations or gene copy loss 
was investigated in vitro using melanoma cell lines.
Results: Unsupervised hierarchical clustering analysis of SCNAs identi-
fied two groups corresponding to thin and thick melanomas, suggesting 
distinct genetic differences between those two groups. The most striking 
difference between them was the much greater abundance of SCNAs 
in thick melanomas, whereas mutation frequency did not significantly 
change between the two groups. Interestingly, we found novel mutations 
and focal SCNAs in genes that are embryonic regulators of axon guid-
ance, predominantly in thick melanomas. Analysis of microarray datasets 
provided further support for a potential role of Ephrin receptors A4 and 
A7 in melanoma progression. Among regions with copy loss we identi-
fied PARK2, an E3 ubiquitin-protein ligase with putative tumor suppres-
sor role. Functional analysis in melanoma cell lines confirmed that PARK2 
silencing enhanced whereas PARK2 over-expression inhibited melanoma 
cell growth. Finally, we have identified a set of SCNAs, including amplifica-
tion of BRAF and of the epigenetic modifier EZH2, that are specific for the 
group of thick melanomas that developed metastasis during follow-up.
Conclusions: Our data reveal that mutations occur early during mela-
noma development, whereas SCNAs seem to be involved in mela-
noma progression, and suggest that thin and thick melanomas from 
the outset might be two different subtypes of melanomas that differ in 
their tendency to undergo SCNAs.
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Background: Anti-programmed cell death-1 (PD-1) antibodies can be 
a risk factor for insulin dependent diabetes mellitus as a side-effect, 
probably due to an inappropriate activation of T cells [1, 2, 3]. Very 
small number of cases have been reported and few data are available 
about patients treated with anti-PD-1 antibodies with of other risk fac-
tors for diabetes, included combined use with other immune modula-
tors, pancreatic metastases and preexisting type 2 diabetes [4].
Here we report our recent experience of a patient underwent pan-
creatoduodenectomy for pancreatic metastases from melanoma and 
treated with Nivolumab.
Case report: A 45-year-old man was admitted to our Oncology Unit in 
June 2016 with the diagnosis of metastatic melanoma. ECOG Perfor-
mance Status was 0 and no comorbidities were reported. In May 2016 
pathological lymph nodes in left inguinal region were removed surgi-
cally and the histological diagnosis was metastases from melanoma, 
BRAF mutated. In June 2016, he underwent pancreatoduodenectomy 
for metastases of melanoma in the head of the pancreas. On July 2016, 
he started Nivolumab administered at 3  mg/kg intravenously, every 
2  weeks. Basal glycemia, islet autoantibodies, haemoglobin A1c and 
serum C-peptide levels were normal. The last haematological reports, 
performed on 16 August 2016, showed hyperglycemia (131 mg/dl-ref-
erence range:74–106), normal levels of serum C-peptide, absence of islet 
autoantibodies and elevated haemoglobin A1c level (42  mmol/mol—
reference range: 20.0–38.0). At this moment, he continues Nivolumab 
and he is constantly monitored for his increased risk of diabetes.
Discussion: Our research in the literature found only four reports (eight 
cases) of diabetes mellitus during treatment with anti- PD-1 antibodies 
and, among these, only a case of patient with pancreatic metastases, 
probably also due to the rarity of pancreatic metastases from mela-
noma [3,4,5]. All described reports develop acute severe hyperglyce-
mia with ketoacidosis or low/undetectable C-peptide, with a rapid fall 
into insulin-dependence; the islet autoantibodies are often negative. 
Considering the rapid onset, severity and potential mortality of those 
situations, routine measurement of both haemoglobin A1c and blood 
glucose levels is necessary during administration of anti-PD-1 antibod-
ies [3]. Our single-patient experience demonstrates that administration 
of Nivolumab is safe and well tolerated even in presence of risk factors 
for diabetes. However, further accumulation of cases, evidence and fur-
ther studies are required to clarify the incidence of diabetes mellitus, 
the pathogenesis and the background factors and to identify biomark-
ers predictive of anti-PD-1 therapy-related diabetes, for the prevention 
and the timely diagnosis of this serious adverse event [3, 4].
Consent to publish: Authors have written informed consent from the 
patient to publish.
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Background: The melanoma is one of the major cancers that occur 
at a young age. In Italy it is the third most common cause of cancer 
in people under the age of 50  years old. The incidence of malignant 
melanoma is on the rise in both men (+3.6%/year) than in women 
(+3.7%/year).
With the advent of PD-1 inhibitor (anti-programmed-death-1, pem-
brolizumab, nivolumab) there has been an important evolution in the 
treatment of advanced unresectable or metastatic melanoma, associ-
ated with decrease morbidity and mortality.
Safety and tolerability of the cancer drugs are not well known for 
the rapid commercialization. This study investigated the occurence 
and characteristics of adverse drug reactions immunological 
treatment-related.
Materials and methods: A retrospective observational study on sus-
pected adverse drug reactions (ADRs) was conducted from January 
2015 to August 2016. We extracted from Pharmacovigilance National 
Network (RNF) and from the European database of ARDs (Eudravigi-
lance.org) the reactions occurred during melanoma disease treated 
with pembrolizumab (Keytruda®) or nivolumab (Opdivo®).
Results: In the period of study, 25 ADRs by PD-1 inhibitor are included 
in the RNF. 7 ADRs reported when PD-1 used as part of malignant mel-
anoma therapy: 6 Keytruda® (4 severe) and 1 Opdivo®. The only ADR 
reported against Opdivo® and considered “ not serious “ highlighted in 
female patient under 65, resulted in a transient state of thrombocyto-
penia. 60% of ADRs relating to Keytruda® were found in patients par-
ticipants in clinical trials. In particular relevant are 2 reports: one severe 
reactions (diarrhea) and the other non-severe reaction (itching). Both 
ADRs occurred in patients (M/F 1:1) treatment-experienced with pem-
brolizumab and in which diagnosed with melanoma by more than 
10  years. Although there had been adverse reactions no patient dis-
continued treatment with Keytruda® or Opdivo®. The Opdivo®’s ADRs 
is the only case in both databases. All other ADRs encountered at the 
national level are in line with those reported in the Eudravigilance.org.
Conclusion: Our data showed an acceptable tolerability profile. Every 
ADR was known and reported in data sheet. Post-marketing surveil-
lance is a research tool needed to deepen the benefit-risk profile, 
especially in oncology. High toxicity of antineoplastic therapy deter-
mines numerous ADRs that are not always reported, in fact in the RNF 
the number of ADRs reported for this class of drugs is by far lower than 
that of the other classes.
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Background: Adenosine is an ATP metabolite, generated in the extra-
cellular space by the ectonucleotidase CD73. In the tumor micro-
environment adenosine impairs anti-tumor immunity, through the 
Gs-coupled receptors A2A and/or A2B, promoting tumor growth 
and survival. Blockade of CD73 or A2AR subtype has been shown to 
improve the anti-tumor immune response. Inhibitors of these targets 
are currently in Phase I clinical trials in cancer patients. Whilst A2AR is 
the most thoroughly characterized receptor involved in the immuno-
suppressive effects of adenosine, A2B is emerging as a potential anti-
cancer target.
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Materials and methods: To investigate the mechanisms through 
which the A2BR pharmacological modulators impact the primary 
tumor growth a syngeneic mouse model of melanoma was used. B16.
F10 melanoma-bearing mice were treated with a selective antagonist 
of A2BR, PSB1115. Myeloid and lymphoid leucocyte populations were 
analyzed in the tumor tissue, tumor draining lymph node and spleen 
harvested from control and PSB1115-treated groups. The effects of 
A2BR modulators were also examined in tumor stroma cells, including 
endothelial cells and melanoma-associated fibroblasts. The therapeu-
tic potential of the A2BR blocker was tested in combination with some 
chemotherapeutics, such as dacarbazine.
Results: Our results show that A2BR inhibition with PSB1115 signifi-
cantly delayed tumor growth in mice. PSB1115 treatment decreased 
the accumulation of myeloid-derived suppressor cells (MDSCs) in the 
tumor microenvironment but not in non-tumoral peripheral organs. 
This effect was associated with an increased numbers of tumor-infil-
trating CD8+ T cells and NKT cells, and enhanced levels of IFN-γ and 
granzyme B. The anti-tumor effects of PSB1115 was indeed lost in 
melanoma-bearing nude mice lacking of T cells. The effects of A2BR 
inhibitor was also evaluated on tumor stroma cells. Tumor angiogene-
sis in PSB1115-treated mice was inhibited and the expression levels of 
tumor VEGF reduced. Furthermore we found that PSB1115 treatment 
impacted the function of melanoma-associated fibroblasts in produc-
ing FGF2 and CXCL12, which contribute to enhance tumor growth. 
Treatment of animals with PSB1115 enhanced the anti-tumor activity 
of dacarbazine and anti-VEGF agents.
Conclusions: Pharmacological blockade of A2BR inhibits the growth 
of syngeneic melanoma in  vivo. PSB1115 treatment decreases the 
number of tumor MDSCs, increases the number of tumor-infiltrating 
T lymphocytes, affects tumor angiogenesis and the activation of mel-
anoma-associated fibroblasts. Therefore data from animal studies sup-
port the therapeutic potential of A2B blockers in melanoma.
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Background: CTLA4- blocking antibodies induced- hypophysitis 
is the most frequent endocrine-adverse events (E-AEs) grade ¾ in 
patients with advanced melanoma. Unlike sporadic hypophysitis, 
immune checkpoint inhibitors-induced an atypical hypophysitis, 
which is more common in men than in women, hyperprolactinemia 
and diabetes insipidus are extremely rare. Finally, visual field defects 
are rare because swelling is not large enough to affect the optic 
chiasma.
Aims: Given the difficult in accurately diagnosing this atypical hypo-
physitis and the poor data supporting establishment of standard sys-
temic therapy options, patients were evaluated within the setting of 
a multidisciplinary team, endocrinologists with expertise in pituitary 
disease, oncologists and neuroradiologists.
Materials and methods: Twenty-one (13 male; age range 27–73 
years) out of 97 patients treated with CTLA4-blocking antibodies for 
advanced melanoma affected by hypophysitis, were studied. Clini-
cal, hormonal and pituitary MRI findings at diagnosis and during the 
follow-up requires a multidisciplinary approach in order to ensure a 
personalized treatment approach.
Results: Hypophysitis with hypopituitarism occurred after the third 
and four CTLA4-blocking antibodies infusion in 19 and 2 out of 21 
patients, respectively. All 21 patients had at least one hormonal 
defects: thyrotroph (n. 15), corticotroph (n. 14) and gonadotroph 
(n.9). None had hyperprolactinemia, diabetes insipidus and visual 
field defects. Pituitary MRI showed a mild/moderate enlarged gland 
in 17 and 4 patients, respectively. All patients had rapid improve-
ment of clinical symptoms during the first and second month after 
the beginning replacement therapy. None of 14 patients showed 
recovery of corticotroph axis at the end of follow-up (12  months). 
Ten out of 15 patients recovered thyrotroph axis at 3  months of 
follow-up.
Conclusion: Early diagnosis and close clinical, biochemical and radio-
logical monitoring are mandatory for correct management of E-AEs. 
Despite other adverse events, hormonal replacement therapy often 
permits patients to continue immunotherapy. So, as the use of immu-
notherapy increases, in order to provide an optimal care a multidisci-
plinary approach is recommended.
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Background: Revealing the very small percentage of highly malignant 
cancer stem cells (CSC) is a major issue for the development of effec-
tive cancer therapeutics. Focusing on the natural humoral immune 
response, human metastatic melanoma tissue sections were inves-
tigated in terms of abnormal glycosilation pattern, as it has major 
importance in tumorproliferation, cancer metastases, invasiveness, 
angiogenesis, signal transfers and apoptosis.
Materials and methods: Freshly removed surgical specimen (n = 134) 
were processed for immunohistochemistry, for antibody profile analy-
sis with tumor infiltrating B (TIL-B) cell Phage Display Assay, genexpres-
sion studies and/or cell cultures. Results: Our immunohistochemical 
findings allowed us to develop a new strategy to reveal cancer stem 
cells by unique tumor-associated disialylated glycosphingolipids (GD3 
gangliosides) and their 9-O acetyl derivatives. The novel antibody pro-
file analysis enabled the detection and selection of those human anti-
body variable region genes that have the specificity to bind to these 
uniquely disialylated glycosphingolipids strongly expressed on sphe-
roid forming CSCs. Other available cancer stem cell markers (CD133, 
Nestin, CD34, ABCB5) were defined paralelly. The selected TIL-B cell 
originated GD3 single chain Fv (scFv) antibody variable gene regions 
became candidates for new chimeric antigen receptor (CAR) third 
generation constructs with non viral vector system to transfect cancer 
targeting immune T cells. Fifteen percent of transfected cells could be 
seen by immunofluorescence labelling, FACS analysis.
Conclusion: A new strategy is shown here to define scFv-s with 
unique specificities to tumor-associated GD3 gangliosides on cancer 
stem cells. For designing human GD3 CARs as new cancer stem cell 
targeting tools, the transposone-based gene delivery system showed 
advantageous characteristics. These results have strong cancer thera-
peutic importance due to using scFv of human origin and the cancer 
stem cell targeting potential.
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Background: One of the concepts raised and defined by the “Immu-
notherapy Summit” [1] as critical was the need to identify hurdles that 
impede effective translation of cancer immunotherapy. Among these, 
the complexity of cancer, tumor heterogeneity and immune escape 
and the lack of definitive biomarkers for assessment of clinical efficacy 
[1,2]. Repeated failures in melanoma therapy has made clear that the 
molecular mechanisms leading to melanoma are still poorly under-
stood and that the main prognostic factors for primary melanoma are 
Breslow thickness, ulceration and mitotic index [3]. However it is now 
accepted that the microenvironment surrounding and interacting with 
the tumoral cell is pivotal in determining the dynamics, organization of 
cutaneous melanoma and its response to therapy [4]. Here we first apply 
a combined approach based on a standardized histochemical and immu-
nohistochemical methodology and a computer-aided image analysis 
systems to investigate how the expression of two Tumor-Associated Anti-
gens (TAAs), i.e. Sperm protein 17 (Sp17) and Squamous Cell Carcinoma 
Antigen 1 (SCCA1), is related to morphological and physical properties of 
the surrounding tumor microenvironment in melanoma tissues.
Materials and methods: 30 primary melanomas were considered in 
the present study [Age: 58 ±  15  years (Range: 36-88  years); Breslow 
index: 4 ± 5 mm, (range: 0.26–22 mm)]. Consecutive paraffin embed-
ded sections were stained by a Sirius red solution and treated with 
antibodies raised against Sp17, SCCA1 (Proteintech Group, Inc), CD34 
and Ki67 (Dako, Italy). All stained slides were analyzed by a computer-
aided image system that automatically selects and quantitatively 
evaluates the immunoreactive entities, their density, distribution, mor-
phology, and distances. Additionally, collagen fibers have been typed 
as Type I or III, using a polarized light microscopy, and their alignment 
determined.
Results: We first evidenced that the expression of SP17 and SCCA1 in 
the tumoral cells is related to the Breslow index, being more expressed 
in superficial lesions than in deepest ones and limited to the lesion. 
We found that all the studied markers changed their density and dis-
tribution pattern according to both TAAs expression. In particular, 
SCCA1+ cells were also Ki67+. SCCA1 was located both in the nuclei 
and in cytoplasm. Deeper lesions were also found more vascularized, 
as shown by the presence of a high number of vessels and more dis-
organized pattern. Collagen fibers showed variable type amounts, and 
change in their alignment.
Conclusions: It is important to develop new diagnostic and therapeu-
tic strategies taking into account the entire tumor microenvironment, 
which consists of “master” cells i.e. tumoral cells, plus “slave” cells, i.e. 
stromal cells, innate and adaptive immune cells, endothelial and lym-
phatic cells, nervous system cells, adipocytes, and the reactive ECM. 
Although it has been demonstrated that the immune contexture of 
tumor microenvironment is able influence the course of the disease 
[5], our results demonstrate that the tumor microenvironment is a 
complex network of cells of different type that dynamically and heter-
ogeneously in space interact each other, exchanging matter, informa-
tion, and energy to advance. The understanding on these interactions 
might improve our knowledge on the dynamics of melanoma, and 
design appropriate therapeutic strategies.
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Background: It has been thoroughly studied the relation between 
host immunity and development of cancer; in the scenario of immu-
notherapy, growing interest has been shown for MDSC, immune-
suppressive myeloid cells significantly expanded in cancer patients. 
Strong evidences support a correlation between levels of circulating 
MDSC and clinical stage, outcome and response to therapy in different 
tumors [1, 2].
After many efforts, MDSC phenotype has been defined (currently, 
there are three main subsets: polymorphonuclear (PMN)-MDSC 
(CD11b+ CD14− CD15+), monocytic (M)-MDSC (CD11b+ CD14+ 
CD15−) and early-stage (e)-MDSC (Lin−(CD3/14/15/19/56)/HLA-
DR−/CD33+) [3]); on the other hand, are still subject of research their 
immunosuppressive actions (that include aminoacid deprivation, 
thanks to enzymes as iNOS and ARG1).
Furthermore, it’s being investigated the use of MDSC as early marker 
for neoplasia and predictive marker to discriminate responder vs non-
responder patients to immunotherapy [5].
Materials and methods: We took blood and processed it fresh from 
11 patients with advanced malignant melanoma; 9 patients received 
immunotherapy (7 anti CTLA-4, 2 anti PD1 drugs). For eight patients 
were available data of pre-/post- treatment. Age-/sex-matched peo-
ple were enrolled as healthy controls. MDSC characterization was 
performed by flow cytometry, using an antibodies-mix approved by 
a proficiency panel [6]. Peripheral blood mononuclear cells (PBMCs) 
were isolated from both patients and healthy donors; by immunomag-
netic sorting we separated CD14+ cells, and analyzed arg1 expression 
by RealTime-PCR.
Results: At 6  months, four patients were free from PD. Applying the 
proficiency panel designed by the Cancer Immunoguiding Program, 
we identified MDSC subpopulations in our patients; the frequen-
cies of MDSC were statistically higher in all the patients compared to 
healthy controls. Interestingly, after treatment with check-point inhibi-
tors MDSC levels decreased. In 5 tested patients arg1 expression was 
increased at baseline and decreased in all the patients after treatment. 
Among our small group of patients, no correlation was found between 
clinical outcome and changes in the number of MDSC.
Conclusions: Despite the small number of patients analyzed, we dem-
onstrated that MDSC are statistically higher in advanced melanoma 
patients compared to healthy controls. Their frequency significantly 
decreased after immunotherapy with check-point inhibitors (i.e. anti-
CTLA4 and PD-1). Besides lowering the number of MDSC, therapy is 
able to induce also a reduction in their functional activity. In fact Arg-
specific mRNA decreased during treatment.
These findings set the basis for a deeper study in melanoma patients of 
functional changes in MDSC at baseline and after therapy. A longer fol-
low-up is also required in order to correlate laboratory data with clinic.
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Background: Sentinel lymph node (SLN) status is one of the most 
important prognostic factor in primary cutaneous melanoma patients. 
Patients submitted to SLN biopsy have a longer disease-free survival 
compared with those who are managed by delayed lymph node dis-
section upon eventual recurrence. To date, the best validated prognos-
tic SN tumour burden parameters are: tumour penetrative depth (TPD) 
beneath the SN capsule, maximum size of SN tumour deposits and 
intranodal location of SN tumour. The aim of the present study was 
to validate the prognostic significance of various SN tumour burden 
micromorphometric features and their correlation with the prediction 
of additional lymph node metastasis, in patients with a positive senti-
nel node.
Materials and methods: In 98 SLN-positive patients treated between 
2013 and 2016 at National Cancer Institute of Naples, Italy, indices of 
primary cutaneous melanoma and SLN tumour burden (Cochran, Starz 
and Rotterdam criterion) were evaluated. Multivariate analysis for the 
prediction of additional lymph node metastasis in patients with a posi-
tive sentinel node and with tumor burden <4% according to Cochran 
method was performed. Of 98 patients, 88 were submitted to com-
plete lymph node dissection (CLND).
Results: CLND was positive for further lymph nodes metastases in 28 
(31,8%) of total 88 cases. Among different tumor burden measure-
ment techniques analyzed, Cochran showed a p-value of 0.02, while 
Starz and Rotterdam 0.3 and 0.17 respectively, for the prediction of 
additional lymph node metastases in patients with positive SLN, while 
primary tumor micromorphometric features were not statistically 
relevant.
Conclusions: In this single-center study, primary tumour and SLN 
tumour burden parameters have been assessed and compared to 
provide reliable prognostic information in SLN-positive patients. Sen-
tinel limph node tumour deposit size <4% separated the cohort of 
patients, predicting negative subsequent CLND and was substantial 
independent predictor of NSN-positivity when >4%. According to this 
and other author’s recent experiences, SLN tumour burden measure-
ment is claimed to become the most prognostic feature that recognize 
melanoma patients into predictive prognostic groups regarding NSN-
positivity and survival outcomes.
